Human low-density lipoprotein-receptor-related protein,LRP-6 ELISA Kit

Code CSB-E08952h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
low density lipoprotein receptor-related protein 6
Alternative Names
ADCAD2 ELISA Kit; C030016K15Rik ELISA Kit; Cd ELISA Kit; FLJ90062 ELISA Kit; FLJ90421 ELISA Kit; LDL receptor related protein 6 ELISA Kit; Low density lipoprotein receptor related protein 6 ELISA Kit; Low-density lipoprotein receptor-related protein 6 ELISA Kit; LRP-6 ELISA Kit; LRP6 ELISA Kit; LRP6_HUMAN ELISA Kit; OTTHUMP00000238979 ELISA Kit; OTTHUMP00000238980 ELISA Kit; OTTHUMP00000238982 ELISA Kit; STHAG7 ELISA Kit
Abbreviation
LRP6
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, tissue homogenates, cell lysates
Detection Range
0.312 ng/mL-20 ng/mL
Sensitivity
0.078 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of Human LRP-6 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %88
Range %83-91
1:2Average %92
Range %86-97
1:4Average %94
Range %88-98
1:8Average %102
Range %98-104
Recovery
The recovery of Human LRP-6 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9488-98
EDTA plasma (n=4)8682-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
202.625 2.729 2.677 2.494
102.146 2.047 2.097 1.914
51.444 1.463 1.454 1.271
2.50.912 0.928 0.920 0.737
1.250.597 0.586 0.592 0.409
0.6250.401 0.416 0.409 0.226
0.3120.287 0.275 0.281 0.098
00.182 0.183 0.183
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This human LRP6 ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human LRP6 in multiple samples, including serum, tissue homogenates, or cell lysates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the LRP6 overexpression has been reported to induce the growth of several types of cancers, including glioblastoma multiforme and gastric cancer. levels in the sample and is measured at 450 nm through a microplate reader.

LRP6 is involved in many biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development. LRP6 is essential for the proper development of different organs in vertebrates, such as Xenopus laevis, chickens, and mice. In humans, LRP6 overexpression and mutations have been found in multiple complex diseases including hypertension, atherosclerosis, and cancers. Clinical studies have shown that LRP6 is implicated in various kinds of cancer, such as bladder and breast cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation.
Gene References into Functions
  1. knockdown of LRP6 inhibited the cell viability by activation of Drp1 in glucose deprived-cardiomyocytes. PMID: 29864925
  2. Three rare missense mutations (c.1514A>G, p.Y505C); c.2984A>G, p.D995G; and c.4280C>A, p.P1427Q) of the LRP6 gene were identified in Chinese NTD patients. The Y505C mutation is a loss-of-function mutation on both WNT/beta-catenin and PCP signaling. The D995G mutation partially lost inhibition on PCP signaling without affecting WNT/beta-catenin signaling. The P1427Q mutation dramatically increased WNT/beta-catenin signa... PMID: 28960852
  3. LRP6 endocytosis proceeds by two routes, depending on the presence of LDL, and that LRP6 controls the intracellular destination of NPC1L1 in hepatocytes. PMID: 28821575
  4. High Expressions of LRP6 is associated with cancer. PMID: 28418856
  5. LRP6 expression was found to be upregulated in oral squamous cell carcinoma tissues, and correlated with a cluster of clinicopathologic parameters, including smoking, drinking, tumor differentiation status, lymph node metastasis and survival time. PMID: 28880263
  6. CCN2 plays a promoting role in hepatocellular carcinoma (HCC)progression through activating LRP6 in a HSPGs-dependent manner. Heparin in combination with chemotherapy has a synergic effect and could be a treatment choice for HCCs with a high CCN2 expression. PMID: 28870205
  7. Increased LRP6 gene expression is associated with colorectal cancer. PMID: 28387660
  8. Therefore, our study demonstrates that miR-183 is a tumor suppressor microRNA that plays a major role in OS. PMID: 29402412
  9. data suggest that LRP6 promotes negative breast cancer cell migration and invasion by regulating the expression and function of S100A4 via the Wnt/beta-catenin signaling pathway PMID: 28247948
  10. sustained activation of Wnt/beta-catenin signaling due to abrogation of Merlin-mediated inhibition of LRP6 phosphorylation may be a cause of Neurofibromatosis type II disease. PMID: 27285107
  11. LRP6 ectodomain becomes highly compact upon complexation with the Wnt antagonist Dkk1, suggesting a potential role for the ectodomain conformational change in the regulation of receptor oligomerization and signaling. PMID: 28052259
  12. identify ANGPTL4 as a Wnt signaling antagonist that binds to syndecans and forms a ternary complex with the Wnt co-receptor Lipoprotein receptor-related protein 6 PMID: 29017031
  13. The authors show that folding of the Wnt signaling coreceptor LRP6 is promoted by ubiquitination of a specific lysine, retaining it in the ER while avoiding degradation. PMID: 27751231
  14. Taken together, this study reveals evidence demonstrating a mechanism by which the LPR6/ GSK3beta/E2F1 axis-upregulated LSH promoted gliomas. PMID: 28042322
  15. Structure of the dual-mode Wnt regulator Kremen1 and insight into ternary complex formation with LRP6 and DKK1 have been presented. PMID: 27524201
  16. VAP1 cleaved the extracellular region of LRP6 at Glu1196-Leu1197, the C-terminus of the 4th propeller domain. This cleavage removes four inhibitory beta-propeller structures, resulting in activation of LRP5/6. PMID: 28425175
  17. We identified a frameshift (c.4594delG, p.Cys1532fs) and a canonical splice-site mutation (c.3398-2A>C, p.?) in LRP6, respectively, in the patient with tooth agenesis (TA) and orofacial clefting (OFC) and in the patient with severe TA only. Mutations in LRP6 cause TA in humans PMID: 26963285
  18. findings revealed an unrecognized role of Caprin-2 in facilitating LRP5/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14, Cyclin Y, and LRP5/6. PMID: 27821587
  19. results suggest that miR-29b inhibits expression of LRP6 and HuR post-transcriptionally, thus playing a role in the regulation of IEC proliferation and intestinal epithelial homoeostasis. PMID: 27089893
  20. Mutant LRP6 Impairs Endothelial Cell Functions Associated with Familial Normolipidemic Coronary Artery Disease. PMID: 27455246
  21. LncRNA PTCSC3 inhibits the proliferation and migration of glioma cells and suppresses Wnt/beta-catenin signaling pathway by targeting LRP6 PMID: 28187755
  22. Accordingly, we propose that the anti-fibrotic activity of adiponectin may be mediated through AdipoR1/R2 receptors PMID: 26797284
  23. findings suggest that rescuing LRP5/6-mediated Wnt signaling improves neuronal cell survival and reduces tau phosphorylation, which support the hypothesis that Wnt signaling might be an attractive therapeutic strategy for managing AD PMID: 25959626
  24. Results suggest that miR-126 functions as a tumor-suppressive miRNA by targeting LRP6 regulating Wnt/beta-catenin signaling pathway in papillary thyroid carcinoma. PMID: 26239517
  25. miR513c functions as a tumor suppressor miRNA, mediated predominantly through the direct suppression of the expression of LRP6. PMID: 26063413
  26. The interaction between Wnt isoforms and their LRP6 cognate receptor depends on the jutting loop present in Wnt3a but absent in Wnt5b. PMID: 25425204
  27. LRP6 and VEGF levels in the vitreous body from patients with proliferative diabetic retinopathy were increased and correlated mutually. PMID: 26120271
  28. Lrp6 binds to Frizzled, preventing Frz-regulated non-canonical Wnt pathway activation and further non-canonical pathway-mediated tumour metastasis. PMID: 25902418
  29. No mutations in LRP5 and LRP6 could be identified PMID: 25783012
  30. LRP6 variants may be associated with risk of ischaemic stroke. PMID: 26031789
  31. Particularly for TNBC associated with Skp2/LRP6 overexpression. PMID: 25358452
  32. Loss-of-Function Mutations in the WNT Co-receptor LRP6 Cause Autosomal-Dominant Oligodontia. PMID: 26387593
  33. LRP6 variants outside of YWTD repeats could potentially predispose embryos to neural tube defectss, whereas Lrp6 modulation of Wnt/planar cell polarity signaling would be more essential than its canonical pathway role in neural tube closure. PMID: 25546815
  34. the metastasis and angiogenesis functions of miR-126-3p were mediated by LRP6 and PIK3R2. PMID: 25240815
  35. High LRP6 expression is associated with glioblastoma. PMID: 25301448
  36. LRP6 (and Wnt signaling) are significantly downregulated in Alzheimer's disease brains. PMID: 25242217
  37. The LRP6 rs10845498 SNP is associated with a reduced risk of lung SCC, while tobacco smoke increases the risk PMID: 24843317
  38. The LRP6 tyrosine mutant increased in signaling activation in response to Wnt3a/beta-catenin stimulation. PMID: 25143377
  39. The results suggested that the lack of affinity between human DKK3 and human LRP5/6 results from: i) insertion of the 7 amino acids, and ii) P258 in human DKK3. PMID: 24743782
  40. results demonstrated that the novel loss-of-function variants identified in this study might contribute to disease liability in a subset of coronary artery disease (CAD) and defects in Wnt signal activation might be important contributing factors for the onset of CAD PMID: 24427284
  41. Rottlerin is a novel LRP6 inhibitor, promoting protein degradation. PMID: 24607787
  42. This study demonstrates the association of rare and novel missense mutations in LRP6 that is an inhibitor rather than an activator of the non-canonical planar cell polarity pathway with human neural tube defects. PMID: 24203697
  43. Data provides the first evidence that LRP6 rs2302685 polymorphism is associated with an increased risk of MI in Chinese subjects, and the association is more evident among younger individuals, which probably due to the elevated LDL-C levels. PMID: 24906453
  44. LRP6 may influence glucose metabolism in type II fibers of human skeletal muscles. PMID: 24457908
  45. Syndecan-1 modulates the cancer stem cell phenotype via regulation of the Wnt and IL-6/STAT3 signaling pathways PMID: 24392029
  46. Data indicate that miR-202 suppresses the expression of LRP6 (low-density lipoprotein receptor-related protein 6) by binding to the 3'-untranslated region (UTR) of its mRNA. PMID: 24704686
  47. LRP6 was identified as a new target of miR-183, and restoration of the expression of LRP6 rescues the effects induced by miR-183 in retinoblastoma cells. PMID: 24289859
  48. GSK3 is sequestered into multivesicular bodies through and interaction between p120-catenin/cadherin and LRP5/6. PMID: 24412065
  49. Results indicate that Lrp6 mediates not only canonical Wnt signaling, but can also modulate non-canonical pathways involving RhoA-dependent mechanisms to impact neurulation, possibly through intracellular complexes with DAAM1. PMID: 23773994
  50. Data show that beta-arrestins regulate Wnt3a-induced low density lipoprotein receptor-related protein 6 (Lrp6) phosphorylation by the regulation of the membrane dynamics of Amer1. PMID: 24265322

Show More

Hide All

Involvement in disease
Coronary artery disease, autosomal dominant, 2 (ADCAD2); Tooth agenesis, selective, 7 (STHAG7)
Subcellular Location
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum. Membrane raft.
Protein Families
LDLR family
Tissue Specificity
Widely coexpressed with LRP5 during embryogenesis and in adult tissues.
Database Links

HGNC: 6698

OMIM: 603507

KEGG: hsa:4040

STRING: 9606.ENSP00000261349

UniGene: Hs.584775

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1